Pegaptanib In 2004, the US Food and Drug Administration (FDA) approved the first intravitreal anti-VEGF therapy, pegaptanib, an RNA oligonucleotide ligand (or aptamer) that binds human VEGF165. Studies showed that it slowed vision loss, but it has since been supplanted by more effective agents.